A detailed history of Barclays PLC transactions in Actinium Pharmaceuticals, Inc. stock. As of the latest transaction made, Barclays PLC holds 42,935 shares of ATNM stock, worth $53,239. This represents 0.0% of its overall portfolio holdings.

Number of Shares
42,935
Previous 42,935 -0.0%
Holding current value
$53,239
Previous $81,000 -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 15, 2024

BUY
$1.72 - $8.0 $56,388 - $262,272
32,784 Added 322.96%
42,935 $81,000
Q2 2024

Aug 14, 2024

SELL
$6.56 - $9.89 $60,470 - $91,166
-9,218 Reduced 47.59%
10,151 $75,000
Q1 2024

May 15, 2024

SELL
$5.0 - $9.2 $91,735 - $168,792
-18,347 Reduced 48.65%
19,369 $152,000
Q4 2023

Feb 15, 2024

BUY
$4.02 - $6.08 $132,917 - $201,029
33,064 Added 710.75%
37,716 $192,000
Q3 2023

Nov 07, 2023

SELL
$5.91 - $7.37 $3,150 - $3,928
-533 Reduced 10.28%
4,652 $27,000
Q2 2023

Aug 03, 2023

SELL
$7.15 - $9.39 $360,910 - $473,979
-50,477 Reduced 90.68%
5,185 $39,000
Q1 2023

May 04, 2023

BUY
$8.51 - $14.26 $473,683 - $793,740
55,662 New
55,662 $526,000

Others Institutions Holding ATNM

About Actinium Pharmaceuticals, Inc.


  • Ticker ATNM
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 25,184,700
  • Market Cap $31.2M
  • Description
  • Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant (BMT) or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly re...
More about ATNM
Track This Portfolio

Track Barclays PLC Portfolio

Follow Barclays PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.